Lava Therapeutics BV, a biotechnology company, is dedicated to developing a portfolio of gamma-delta bispecific T-cell activators (gamma-delta bsTCE) for the treatment of solid tumors and hematologic malignancies based on its platform. The company is headquartered in Utrecht, the Netherlands.